Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Insider Sells $113,675.95 in Stock

Key Points

• Insider Stephen Machatha sold 22,073 shares of Aldeyra Therapeutics for approximately $113,676 at an average price of $5.15, reducing their ownership by 9.05%.
• Aldeyra Therapeutics recently reported an EPS of ($0.16), outperforming the consensus estimate of ($0.21) by $0.05.
• Several institutional investors have increased their stakes in Aldeyra, with Kingdon Capital Management purchasing a stake worth approximately $4.48 million.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) insider Stephen Machatha sold 22,073 shares of Aldeyra Therapeutics stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the completion of the sale, the insider owned 221,799 shares of the company's stock, valued at approximately $1,142,264.85. The trade was a 9.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Aldeyra Therapeutics Trading Up 0.2%

Shares of ALDX stock traded up $0.01 during trading hours on Wednesday, hitting $5.37. 868,933 shares of the company were exchanged, compared to its average volume of 1,130,444. The business has a 50 day moving average of $4.30 and a two-hundred day moving average of $4.25. Aldeyra Therapeutics, Inc. has a 52 week low of $1.14 and a 52 week high of $7.20. The company has a market capitalization of $321.66 million, a PE ratio of -6.32 and a beta of 0.76.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.05. On average, research analysts forecast that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current year.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several institutional investors have recently bought and sold shares of the company. Kingdon Capital Management L.L.C. bought a new stake in shares of Aldeyra Therapeutics during the 1st quarter worth approximately $4,479,000. Raymond James Financial Inc. bought a new stake in Aldeyra Therapeutics in the 4th quarter valued at $3,628,000. Invesco Ltd. raised its stake in Aldeyra Therapeutics by 1,575.7% in the 1st quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company's stock valued at $2,882,000 after acquiring an additional 471,231 shares during the period. AQR Capital Management LLC raised its stake in Aldeyra Therapeutics by 456.3% in the 1st quarter. AQR Capital Management LLC now owns 392,555 shares of the biotechnology company's stock valued at $2,257,000 after acquiring an additional 321,992 shares during the period. Finally, 683 Capital Management LLC bought a new stake in Aldeyra Therapeutics in the 4th quarter valued at $1,447,000. Institutional investors own 59.71% of the company's stock.

Analyst Upgrades and Downgrades

ALDX has been the subject of several analyst reports. Wall Street Zen upgraded Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Aldeyra Therapeutics in a research note on Monday, May 19th.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.